Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Recruiting · NCT07244393 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | Phase 1 | 2026-10-07 | NCT07244393 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cellbion Co., Ltd. | 2 |
| Merck Sharp & Dohme LLC | 650 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Seoul National University Hospital | Seoul | South Korea | 183 |